News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galapagos NV (GLPG.BR) to Present at the 31st Annual J. P. Morgan Healthcare Conference



1/7/2013 9:53:06 AM

MECHELEN, BELGIUM--(Marketwire - January 06, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG) announced today that Onno van de Stolpe, CEO of Galapagos, will present at the 31(st) annual J. P. Morgan Healthcare Conference on Thursday, January 10(th) at 9:00 a.m. (PST) / 12 p.m. (EST)/ 18.00 (CET) in San Francisco. The presentation will be held in the Elizabethan A/B room in the Westin St. Francis and will also be webcast.

Click here to access the webcast or go to www.glpg.com to access a PDF of the presentation slides. A replay of the presentation will be available for 90 days.

About Galapagos
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing its JAK1 inhibitor GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs. The Galapagos Group has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com


This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward- looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE [HUG#1668408]


CONTACT

Galapagos NV
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES